| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043519579 |
| P356 | DOI | 10.1186/S40064-015-1545-Y |
| P932 | PMC publication ID | 4666886 |
| P698 | PubMed publication ID | 26693102 |
| P5875 | ResearchGate publication ID | 285383187 |
| P50 | author | Luca Faloppi | Q55112122 |
| Maristella Bianconi | Q55816143 | ||
| Mirco Pistelli | Q59695717 | ||
| Alessandro Bittoni | Q87479555 | ||
| Riccardo Giampieri | Q91714473 | ||
| Stefano Cascinu | Q38359621 | ||
| Mario Scartozzi | Q42811548 | ||
| Michela Del Prete | Q48342895 | ||
| P2860 | cites work | Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. | Q53232788 |
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group | Q80704657 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 | ||
| Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial | Q33658659 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial | Q34581085 | ||
| Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group | Q39332358 | ||
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
| Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. | Q43125608 | ||
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 743 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | SpringerPlus | Q24055190 |
| P1476 | title | Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis | |
| P478 | volume | 4 |
| Q59353428 | Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells |
| Q37689114 | Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis |
| Q33902814 | Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis |
| Q64885732 | Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study. |
| Q64081314 | Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer |
| Q41242339 | Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts |
Search more.